Emine Mine Soylu | Plant Pathology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Emine Mine Soylu | Plant Pathology | Best Researcher Award

Hatay Mustafa Kemal University | Turkey

Prof. Dr. Emine Mine Soylu is a prominent academic in the field of plant pathology, with a career spanning over three decades dedicated to plant protection, host-pathogen interactions, and disease management strategies in crops. She began her professional journey as a Research Assistant at Akdeniz University and has since contributed significantly to scientific research through both experimental studies and scholarly publications. Her work is widely recognized, with a particular focus on the identification and control of fungal and bacterial diseases in economically important plants. Prof. Soylu has published 54 scientific documents in internationally refereed journals and has amassed a total of 3,749 citations, reflecting the substantial impact of her work in the field. Her h-index is 25, indicating consistent and high-quality contributions to science over the years. Her research includes first reports of various plant diseases in TΓΌrkiye and in-depth studies on disease resistance mechanisms and biochemical plant responses. Prof. Soylu’s contributions continue to shape the future of sustainable agriculture and plant health, and her collaborations extend across national and international scientific communities. Her scholarly output and citation metrics demonstrate her strong influence in the field of phytopathology and plant-microbe interactions.

Profiles: Google Scholar | Scopus |Β  Orcid

Featured Publications:

  • “Preliminary Characterization of Race-Specific Elicitors From Peronospora parasitica and Its Ability to Elicit Phenolic Accumulation in Arabidopsis”

  • “First Report of Downy Leaf Spot of Walnuts Caused by Microstroma juglandis in Turkey”

  • “Induction of Disease Resistance by the Plant Activator, Acibenzolar-S-methyl (ASM), Against Bacterial Canker (Clavibacter michiganensis subsp. michiganensis) in Tomato Seedlings”

  • “First Report of Powdery Mildew Caused by Erysiphe heraclei on Dill (Anethum graveolens) in Turkey”

  • “Light and Electron Microscopy of the Compatible Interaction Between Arabidopsis and the Downy Mildew Pathogen Peronospora parasitica”

  • “Induction of Defence Related Enzymes and Resistance by the Plant Activator Acibenzolar-S-methyl in Tomato Seedlings Against Bacterial Canker Caused by Clavibacter michiganensis subsp. michiganensis”

  • “First Report of Cercospora Leaf Spot on Swiss Chard Caused by Cercospora beticola in Turkey”

  • “First Report of Phloeospora Leaf Spot on Mulberry Caused by Phloeospora maculans (=Cylindrosporium maculans) in the Eastern Mediterranean Region of Turkey”

  • “Induction of Disease Resistance and Antioxidant Enzymes by Acibenzolar-S-methyl Against Bacterial Canker (Clavibacter michiganensis subsp. michiganensis) in Tomato”

  • “First Report of Powdery Mildew Caused by Podosphaera phaseoli (syn. Sphaerotheca phaseoli) on Cowpea (Vigna sinensis) in Turkey”

 

 

 

 

 

 

 

 

 

 

Nives Jonjić | Cancer Cell Biology | Women Researcher Award

Published on by Cell Biologist

Prof. Dr. Nives Jonjić | Cancer Cell Biology | Women Researcher Award

Prof. Dr. Nives Jonjić | Department of Pathology and Citology, CHC Rijeka | Croatia

Prof. Nives JonjiΔ‡, MD, is a Full Professor Emeritus at the Department of General Pathology and Pathological Anatomy, Faculty of Medicine, University of Rijeka, Croatia. With a distinguished academic and clinical career spanning decades, Prof. JonjiΔ‡ has made significant contributions to oncologic and molecular pathology. Her work focuses on understanding molecular markers in tumor progression and their diagnostic and prognostic relevance. As a prolific researcher and author, she has published extensively in high-impact international journals and collaborated with leading experts in pathology and oncology. Known for her diagnostic precision and dedication to academic mentorship, she has guided numerous medical students, residents, and doctoral candidates. Her legacy includes groundbreaking studies on biomarkers like Nectin-2 and Nectin-4 and rare pathologic entities. Prof. JonjiΔ‡’s leadership and scientific rigor make her a prominent figure in Croatian medical science and a respected name in international pathology circles.

Publication Profile:

Scopus

βœ… Strengths for the Award:

  1. Extensive Academic and Clinical Experience
    Prof. Nives Jonjić is a Full Professor Emeritus in pathology with decades of clinical, academic, and research experience, making her a veteran in her field.

  2. Strong Research Track Record

    • Multiple first and co-authored papers in peer-reviewed journals such as Current Issues in Molecular Biology, Pathology Research and Practice, and Clinical Pathology.

    • A clear focus on oncologic pathology, including biomarkers (e.g., Nectin-2 and Nectin-4), angiogenesis, lymphomas, and myelomas.

  3. Mentorship and Academic Leadership
    She has played a key role in mentoring junior scientists, guiding doctoral research, and shaping curriculum and teaching in pathology at the University of Rijeka.

  4. Work on Rare and Challenging Diagnoses
    Her research includes diagnostic dilemmas and rare malignancies, showing depth and clinical relevance, such as CD20-negative B-cell lymphomas and extranodal Hodgkin lymphomas.

  5. Contribution to Women in Science
    As a senior female figure in medicine, her position as a full professor and mentor has made her a role model in advancing women’s participation in scientific leadership roles.

πŸ“‰ Areas for Improvement:

  1. Broader International Visibility
    While her research is of high quality, greater engagement in global collaborative projects, EU-funded consortia, or as a keynote speaker in international forums could enhance her visibility outside Croatia.

  2. Higher Citation Metrics and Impact Index
    Although several of her publications are impactful, a few are recent and not yet widely cited. Participation in meta-analyses or review articles might help amplify her citation footprint.

  3. Digital and Social Research Presence
    A more proactive presence on platforms like ResearchGate, ORCID, or Google Scholar and involvement in open-access science movements could increase accessibility to her work.

πŸŽ“ Education:

Prof. Nives Jonjić completed her Medical Degree (MD) at the Faculty of Medicine, University of Rijeka, where she also pursued her postgraduate education and specialization in pathology. Her academic excellence was evident early in her medical training, leading to her progression into research and teaching. She earned her doctoral degree (PhD) with a focus on tumor biology and pathology. Over the years, she attended various advanced courses and workshops in Europe related to histopathology, immunohistochemistry, and oncologic diagnostics. Her commitment to continuous learning kept her updated with evolving trends in cancer research and molecular pathology. Through rigorous training and international collaborations, she established herself as a scholar deeply engaged with both clinical and experimental pathology. Her educational path reflects a deep integration of medical knowledge, critical inquiry, and a lifelong dedication to academic excellence.

πŸ§ͺ Professional Experience:

Prof. Nives Jonjić has over 35 years of experience in academic medicine and pathology. Beginning as a junior lecturer and advancing through roles of Associate Professor and Full Professor, she served at the Faculty of Medicine, University of Rijeka, where she also led the Department of General Pathology and Pathological Anatomy. Her clinical practice included diagnostic histopathology with subspecialty interests in hematopathology, soft tissue tumors, and gynecologic oncology. She played a key role in curriculum development, faculty mentorship, and postgraduate training. As an expert pathologist, she consulted on complex diagnostic cases nationally and internationally. Beyond clinical and teaching roles, she has been a principal investigator and co-investigator in multiple research projects and has evaluated numerous PhD theses. Her rich experience spans clinical excellence, research leadership, and educational mentorship, making her a pillar in Croatian medical academia.

πŸ† Awards and Honors:

Prof. Nives JonjiΔ‡ has received numerous awards and accolades throughout her career for her contributions to medical research, education, and clinical pathology. Among her honors are institutional recognition for excellence in teaching from the University of Rijeka, national awards for research contributions, and commendations from Croatian medical societies. She has also been invited to deliver keynote lectures at international conferences and served as a peer reviewer for esteemed pathology journals. Her election as Full Professor Emeritus reflects the high regard in which she is held by her peers and institution. Prof. JonjiΔ‡ has been actively involved in academic boards and ethical committees and received acknowledgments for advancing women’s leadership in medicine. Her work continues to inspire future generations of medical researchers and clinicians, and her accolades affirm her dedication to science, education, and healthcare.

πŸ”¬ Research Focus:

Prof. Jonjić’s research primarily focuses on tumor pathology, with special emphasis on the expression and role of molecular biomarkers such as Nectin-2, Nectin-4, osteopontin, and NF-ΞΊB in cancer progression, diagnosis, and prognosis. Her studies span various malignancies including squamous cell carcinomas, glial tumors, lymphomas, and multiple myeloma. She is also engaged in investigating rare and diagnostically challenging pathological conditions, contributing to more accurate clinical-pathologic correlations. Her recent research has emphasized angiogenesis, immune profiling, and the tumor microenvironment. She employs advanced histopathological and immunohistochemical techniques to support translational applications in pathology. Through collaboration with multidisciplinary teams, her work bridges laboratory findings with clinical decision-making. Her research is widely cited, reflecting its importance in improving diagnostic accuracy and treatment stratification in oncology. Prof. Jonjić’s academic leadership and focus on innovative diagnostic markers make her a central figure in Croatian cancer research.

πŸ“š Publications Top Notes:

  1. πŸ—£οΈ Laryngeal Squamous Cell Carcinoma Is Characterized by a Stronger Expression of Nectin-4 Compared to Nectin-2

  2. 🧠 The Prognostic Significance of Nectin-2 and Nectin-4 Expression in Glial Tumors

  3. πŸ’‰ Anti-angiogenic Effect of Bortezomib Treatment in Multiple Myeloma Associated with Lower NF-ΞΊB and OPN Expression

  4. πŸ”¬ Primary Nodal Unclassifiable CD20 Negative Diffuse Large B-cell Lymphoma With Dual IgK and TCR Gene Rearrangement

  5. 🦴 Angiogenesis and Osteopontin Expression in Paraskeletal Myeloma With Plasmablastic Morphology

  6. πŸ§ͺ Diagnostic Challenge of Soft Tissue Extranodal Hodgkin Lymphoma in Core-Needle Biopsy

  7. πŸ’Š Lichen Planus Pigmentosus-like Reaction to Pirfenidone in Idiopathic Pulmonary Fibrosis

  8. 🦷 Recurrent Adamantinoma With Fibrous Dysplasia-like Feature

  9. πŸ’‰ Adalimumab as a Risk Factor for Development of Melanocytic Lesions

  10. 🧬 Expression Profiles of Metallothionein-I/II and Megalin/LRP-2 in Uterine Cervical Lesions

🏁 Conclusion:

Prof. Nives Jonjić is a highly suitable candidate for the Research for Women Researcher Award. Her scholarly contributions in pathology, especially tumor diagnostics and molecular markers, are significant and clinically relevant. Her work is anchored in academic integrity and mentorship, fostering the next generation of medical scientists. While global visibility could be enhanced, her regional impact, sustained productivity, and role as a senior academic make her a strong and deserving nominee.

 

Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Published on by Cell Biologist

Mr. Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Mr. Wei Xue , Renji Hospital, School of Medicine, Shanghai Jiaotong University , China

Dr. Xue Wei, M.D., Ph.D., is a distinguished urologist, professor, and researcher specializing in genitourinary oncology. Currently serving as the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, he also leads its Department of Urology. With over 150 publications, including 100+ SCI-indexed papers, Dr. Xue is a leading expert in minimally invasive urological surgeries, particularly robotic-assisted procedures. He has made significant contributions to prostate cancer treatment and multidisciplinary approaches for metastatic prostate cancer. Dr. Xue is an executive member of various prestigious medical organizations, including the Chinese Medical Association and the European Association of Urology. His groundbreaking research and clinical excellence have earned him multiple accolades, including “Shanghai Leading Talent” and “Outstanding Academic Leader.” With a strong dedication to advancing medical technology and patient care, Dr. Xue continues to shape the future of urological oncology through his pioneering work in surgery, research, and mentorship.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contributions πŸ“š – Dr. Xue Wei has over 150 publications, including 100+ SCI-indexed papers, highlighting his impactful work in genitourinary oncology.

  2. Leadership & Influence 🌍 – As Vice President of Renji Hospital and Director of Urology, he plays a crucial role in shaping the future of urological research and treatment.

  3. Clinical Expertise πŸ₯ – He is an expert in robot-assisted and minimally invasive surgeries, particularly nerve-sparing radical prostatectomy and multidisciplinary management of metastatic prostate cancer.

  4. High-Impact Research Grants πŸ’° – Principal investigator for 12 key research projects, including those funded by the National Natural Science Foundation of China.

  5. Prestigious Recognitions πŸ† – Titles like Shanghai Leading Talent and Outstanding Academic Leader reflect his excellence in academia and clinical practice.

πŸ“Œ Areas for Improvement:

  1. Citations & Impact Factor Growth – While his publication count is high, increasing citations and impact factor of his papers would further establish global recognition.

  2. Global Collaboration – Expanding international partnerships and multicenter clinical trials could enhance his research influence beyond China.

  3. Innovative Breakthroughs – While excelling in robotic-assisted surgery, pioneering novel therapeutic strategies could further elevate his status as a global thought leader.

πŸŽ“ Education:

Dr. Xue Wei completed his M.D. and Ph.D. in Urology at Shanghai Jiao Tong University School of Medicine, a premier institution in China known for its rigorous medical training and research excellence. He further honed his expertise through international academic collaborations, including a tenure as a Visiting Associate Professor at the MD Anderson Cancer Center, USA. His academic journey was marked by intensive research in genitourinary oncology, robotic-assisted surgeries, and advanced treatment modalities for prostate and renal cancers. Over the years, he has received advanced training in minimally invasive urological surgery, leveraging cutting-edge technology to improve surgical outcomes. His strong academic foundation, combined with a commitment to innovation, has made him a globally recognized expert in urological oncology. Through continuous education and research leadership, Dr. Xue remains at the forefront of medical advancements, ensuring his contributions have a lasting impact on both clinical practice and scientific research.

πŸ’Ό Experience:

Dr. Xue Wei boasts a distinguished career spanning decades in clinical practice, research, and academic leadership. He is the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, and Director of its Department of Urology. As a key figure in the Chinese and international urology communities, he holds executive positions in prestigious organizations such as the Chinese Medical Association, European Association of Urology, and American Urological Association. Dr. Xue specializes in minimally invasive and robotic-assisted urological surgeries, pioneering advanced techniques in radical prostatectomy and cancer treatment. His leadership extends to mentoring doctoral students and overseeing high-impact research projects funded by national and municipal grants. His role as a principal investigator in groundbreaking studies has led to over 150 peer-reviewed publications. With his clinical expertise, surgical innovations, and research contributions, Dr. Xue remains a leader in shaping the future of urological oncology.

πŸ† Awards & Honors:

Dr. Xue Wei has earned numerous prestigious accolades in recognition of his contributions to urological research and clinical excellence. Among his most notable honors are:

  • Shanghai Leading Talent 🌟

  • Outstanding Academic Leader, Shanghai πŸ…

  • Shanghai Medical Leading Talent πŸŽ–οΈ

  • Shanghai Craftsman & Shanghai Medical Craftsman πŸ†

As a globally recognized expert, Dr. Xue’s pioneering work in robotic-assisted surgery and genitourinary oncology has solidified his reputation as a leading academician and clinician. His dedication to advancing minimally invasive surgery and cancer treatment has not only influenced medical practice in China but also gained international recognition. He serves as a mentor and research leader, shaping the next generation of urologists. With his exceptional achievements, Dr. Xue continues to set benchmarks in urological science, making him a strong contender for the Best Academic Researcher Award.

πŸ”¬ Research Focus:

Dr. Xue Wei’s research primarily focuses on genitourinary oncology, with a particular emphasis on prostate cancer, kidney cancer, and minimally invasive surgery. He has led multiple high-impact studies on robot-assisted laparoscopic procedures, multidisciplinary management of metastatic prostate cancer, and biomolecular mechanisms of cancer progression. His work in precision medicine and targeted therapies has contributed to advancements in prostate cancer treatment, enhancing survival outcomes and treatment efficacy.

As the principal investigator of 12 research projects funded by the National Natural Science Foundation of China and the Shanghai Municipal Education Commission, Dr. Xue has pushed the boundaries of medical innovation. His recent research explores the role of m6A RNA modifications, immunotherapy, and cancer stem cells in drug resistance and tumor aggressiveness. His contributions have transformed clinical practices, bridging the gap between cutting-edge research and real-world patient care, making him a global leader in urological oncology research.

πŸ“š Publications Top Notes:

  1. AGD1/USP10/METTL13 Complexes Enhance Cancer Stem Cells Proliferation and Diminish the Therapeutic Effect of Docetaxel πŸ”¬πŸ§¬

  2. Specific Activation of cGAS-STING Pathway by Manganese-Doped Bioactive Glasses for Boosting Systemic Tumor Immunotherapy πŸ₯πŸ§ͺ

  3. Osalmid Sensitizes Clear Cell Renal Cell Carcinoma to Navitoclax Through a STAT3/BCL-XL Pathway πŸ₯πŸ’Š

  4. Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer πŸ”Žβš•οΈ

  5. Open Nephron-Sparing Surgery Strategy for Renal Angiomyolipoma with Vena Cava Thrombus πŸ₯πŸ”¬

  6. A Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma πŸ’‰πŸ”¬

  7. Proportion of Gleason Score β‰₯8 Prostate Cancer on Biopsy and Tumor Aggressiveness in East Asian vs. Non-East Asian Men πŸ§¬πŸ§‘β€βš•οΈ

  8. Iron-Loaded Cancer-Associated Fibroblasts Induce Immunosuppression in Prostate Cancer πŸ©ΈπŸ›‘οΈ

  9. A Multi-Classifier System Integrated by Clinico-Histology-Genomic Analysis for Predicting Recurrence of Papillary Renal Cell Carcinoma πŸ₯πŸ“Š

πŸ… Conclusion:

Dr. Xue Wei is a highly suitable candidate for the Best Academic Researcher Award due to his exceptional contributions in urological oncology, leadership in clinical research, and dedication to innovation. His extensive academic output, surgical expertise, and impact on medical education make him a leading figure in his field. Enhancing global collaborations and high-impact publications would further solidify his legacy as a world-class researcher. πŸš€